In a phase Ib trial, led by Naval Daver and Michael Andreeff at MD Anderson Cancer Center, researchers evaluated the combination of Venclexta (venetoclax) and idasanutlin in 56 patients with R/R AML who were unfit for chemotherapy. IDH1/2 and RUNX1 mutations were associated with higher composite complete remission rates of 50% and 45%, respectively, and were linked to therapy sensitivity.
Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.
